MATTHEW FRANK BROWN,ALPAY DERMENCI,ANDREW FENSOME,BRIAN STEPHEN GERSTENBERGER,MATTHEW MERRIL HAYWARD,DAFYDD RHYS OWEN,STEPHEN WAYNE WRIGHT,LI HUANG XING,XIAOJING YANG
申请号：
NI201800080
公开号：
NI201800080A
申请日:
2018.08.03
申请国别(地区):
NI
年份:
2018
代理人:
摘要：
1. A compound with the following structure: (I) or a salt acceptable on the drug, or a compound acceptable on the drug, or a salt acceptable on the drug, wherein a, a 'and a are "independent of O, C = O, Cr' or N-R",Where R and R can be independent of H, amino, n7cor6,Cor6，-Conr7r8，C1-C6 asphalt or hydroxy (C1-C6 asphalt),R "may or may not exist, and exists anywhere permitted by the Valencia rules, and does not exceed a, a" and a "yes or C = 0； R0 and R are independent h, Br, Cl, f or C1-C6 tar； R1 is h, C1-C6 tar or hydroxy (C1-C6 tar)；R2 is selected from the group consisting of H, C1-C6 tar, C1-C6 alcox and hydroxy (C1-C6 tar),1. Phenyl (C1-C6 tar)；Thyroid gland, heterosexual, heterosexual,-Cor6，-O'Shea 6-6-N7Cor6，-Conr7r8，Y - (CH2) N-W, where W is cyanide, hydroxi, c3-c8 cycloquilo, so2n7r8 and - so2-r9,R9 is C1-C6 asphalt, c3-c8 cyclopropyl, heterocyclic or heterocyclic； in this case, each asphalt, cyclopropyl, heterocyclic or heterocyclic asphalt may not be replaced or replaced by halogenated, cyanogen, hydroxy or C1-C6 asphalt； X is c-r3 or N, in this case, R3 may be h or C1-C6 asphalt； R4 and R5 are independent h, ammonia water, C1-C6 asphalt or hydroxy (C1-C6 asphalt)；R6，R7 and R8 are respectively h, C1-C6 asphalt, C1-C4 alcoxi (C1-C6 asphalt),O c3-c8 cyclopentyl, i.e. C1-C6 tar, can be selectively substituted with halogen, CN or hydroxyl； or R7 and R8, together with these atoms, can form a 5 or 6-member ring in which halogen, hydroxyl, CN or C1-C6 tar can be selected to replace； n is 0, 1, 2 or 3. Therapeutic methods are also provided, such as quinass January inhibitors and pharmaceutical compounds containing inventive compounds, and combinations of these compounds with other therapeutic agents.Un compuesto que tiene la siguiente estructura: (I) o una sal de este aceptable desde el punto de vista farmacéutico, o un solvato aceptable desde el punto de vista farmacéutico de un compuesto o una sal aceptable desde el punto de vista farmacéutico, en donde A, A'
